Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We studied the effect of peptide AEDG on telomere length and mitotic index of PHA-stimulated blood lymphocytes from young (18-22 years, N=5) and middle-aged (49-54 years, N=6) men. In the younger age group, no significant changes in the mitotic index were detected, while in the middle-aged group, a decrease in this parameter was found in one case. The relative length of telomeric regions of metaphase chromosomes was evaluated by in situ fluorescence hybridization with DNA probes specific to telomeres. After incubation with peptide AEDG, significant changes in the relative telomere length were found in 7 of 11 individuals (3 cases in the younger age group and 4 cases in the middle age group). Significant increase in telomere length after exposure to peptide AEDG was revealed in 5 cases, including two individuals of the younger age group (by 41 and 55%) and three individuals of the middle age group (by 156, 18, and 76%). In one individual of the younger age group and in one of the middle-age group, a significant decrease in telomere length (by 37 and 15%, respectively) was found. A tendency to normalization of telomere lengths was noted: this parameter increased in individuals with initially lower telomere length relative to the group mean value and decreased in individuals with initially longer telomeres compared to the mean length in the group.

About the authors

V. Kh. Khavinson

Department of Biogerontology, St. Petersburg Institute of Bioregulation and Gerontology

Email: miayy@yandex.ru
Russian Federation, Moscow

A. A. Pendina

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

O. A. Efimova

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

A. V. Tikhonov

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

A. S. Koltsova

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

M. I. Krapivin

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

A. V. Petrovskaia-Kaminskaia

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

L. I. Petrova

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg

N. S. Lin’kova

Department of Biogerontology, St. Petersburg Institute of Bioregulation and Gerontology; Department of Therapy, Geriatry, and Anti-Aging Medicine, Academy of Postgraduate Education, Federal Research Clinical Center, Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: miayy@yandex.ru
Russian Federation, Moscow; Moscow

V. S. Baranov

Department of Genomic Medicine, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Email: miayy@yandex.ru
Russian Federation, St. Petersburg


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies